cached image

Douglas R. Galasko, MD - Publications

Affiliations: 
Neuroscience University of California, San Diego, La Jolla, CA 
Area:
Dementia
Website:
http://neurograd.ucsd.edu/faculty/detail.php?id=30

212 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Marshall GA, Sikkes SAM, Amariglio RE, Gatchel JR, Rentz DM, Johnson KA, Langford O, Sun CK, Donohue MC, Raman R, Aisen PS, Sperling RA, Galasko DR. Instrumental activities of daily living, amyloid, and cognition in cognitively normal older adults screening for the A4 Study. Alzheimer's & Dementia (Amsterdam, Netherlands). 12: e12118. PMID 33163609 DOI: 10.1002/dad2.12118  0.32
2020 Weigand AJ, Bondi MW, Thomas KR, Campbell NL, Galasko DR, Salmon DP, Sewell D, Brewer JB, Feldman HH, Delano-Wood L. Association of anticholinergic medication and AD biomarkers with incidence of MCI among cognitively normal older adults. Neurology. PMID 32878992 DOI: 10.1212/WNL.0000000000010643  0.52
2020 Smirnov DS, Galasko D, Edland SD, Filoteo JV, Hansen LA, Salmon DP. Cognitive decline profiles differ in Parkinson disease dementia and dementia with Lewy bodies. Neurology. PMID 32332125 DOI: 10.1212/WNL.0000000000009434  0.52
2020 McKeith IG, Ferman TJ, Thomas AJ, Blanc F, Boeve BF, Fujishiro H, Kantarci K, Muscio C, O'Brien JT, Postuma RB, Aarsland D, Ballard C, Bonanni L, Donaghy P, Emre M, ... ... Galasko D, et al. Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology. PMID 32241955 DOI: 10.1212/WNL.0000000000009323  0.52
2019 Galasko D, Xiao M, Xu D, Smirnov D, Salmon DP, Dewit N, Vanbrabant J, Jacobs D, Vanderstichele H, Vanmechelen E, Worley P. Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer's disease. Alzheimer's & Dementia (New York, N. Y.). 5: 871-882. PMID 31853477 DOI: 10.1016/j.trci.2019.11.002  0.52
2019 Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Damotte V, Naj AC, Boland A, Vronskaya M, van der Lee SJ, Amlie-Wolf A, Bellenguez C, Frizatti A, Chouraki V, Martin ER, Sleegers K, ... ... Galasko DR, et al. Author Correction: Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nature Genetics. PMID 31417202 DOI: 10.1038/s41588-019-0495-7  0.32
2019 Guerreiro R, Escott-Price V, Hernandez DG, Kun-Rodrigues C, Ross OA, Orme T, Neto JL, Carmona S, Dehghani N, Eicher JD, Shepherd C, Parkkinen L, Darwent L, Heckman MG, Scholz SW, ... ... Galasko D, et al. Heritability and genetic variance of dementia with Lewy bodies. Neurobiology of Disease. PMID 30953760 DOI: 10.1016/j.nbd.2019.04.004  0.4
2019 Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Damotte V, Naj AC, Boland A, Vronskaya M, van der Lee SJ, Amlie-Wolf A, Bellenguez C, Frizatti A, Chouraki V, Martin ER, Sleegers K, ... ... Galasko DR, et al. Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nature Genetics. 51: 414-430. PMID 30820047 DOI: 10.1038/s41588-019-0358-2  0.4
2019 Edmonds EC, McDonald CR, Marshall A, Thomas KR, Eppig J, Weigand AJ, Delano-Wood L, Galasko DR, Salmon DP, Bondi MW. Early versus late MCI: Improved MCI staging using a neuropsychological approach. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 30737119 DOI: 10.1016/j.jalz.2018.12.009  0.52
2019 Weissberger GH, Gollan TH, Bondi MW, Nation DA, Hansen LA, Galasko D, Salmon DP. Neuropsychological Deficit Profiles, Vascular Risk Factors, and Neuropathological Findings in Hispanic Older Adults with Autopsy-Confirmed Alzheimer's Disease. Journal of Alzheimer's Disease : Jad. 67: 291-302. PMID 30636736 DOI: 10.3233/JAD-180351  0.52
2019 Korthauer LE, Salmon DP, Festa EK, Galasko D, Heindel WC. Alzheimer's disease and the processing of uncertainty during choice task performance: Executive dysfunction within the Hick-Hyman law. Journal of Clinical and Experimental Neuropsychology. 1-10. PMID 30632903 DOI: 10.1080/13803395.2018.1564813  0.52
2019 Thomas KR, Eppig JS, Weigand AJ, Edmonds EC, Wong CG, Jak AJ, Delano-Wood L, Galasko DR, Salmon DP, Edland SD, Bondi MW. Artificially low mild cognitive impairment to normal reversion rate in Alzheimer's Disease Neuroimaging Initiative. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 30610833 DOI: 10.1016/j.jalz.2018.10.008  0.52
2018 Smirnov DS, Galasko D, Hansen LA, Edland SD, Brewer JB, Salmon DP. Trajectories of cognitive decline differ in hippocampal sclerosis and Alzheimer's disease. Neurobiology of Aging. 75: 169-177. PMID 30579145 DOI: 10.1016/j.neurobiolaging.2018.11.015  0.52
2018 Soria JA, Huisa BN, Edland SD, Litvan I, Peavy GM, Salmon DP, Hansen LA, Galasko DR, Brewer JB, González HM, Rissman RA. Clinical-Neuropathological Correlations of Alzheimer's Disease and Related Dementias in Latino Volunteers. Journal of Alzheimer's Disease : Jad. PMID 30412501 DOI: 10.3233/JAD-180789  0.52
2018 Besser L, Kukull W, Knopman DS, Chui H, Galasko D, Weintraub S, Jicha G, Carlsson C, Burns J, Quinn J, Sweet RA, Rascovsky K, Teylan M, Beekly D, Thomas G, et al. Version 3 of the National Alzheimer's Coordinating Center's Uniform Data Set. Alzheimer Disease and Associated Disorders. PMID 30376508 DOI: 10.1097/WAD.0000000000000279  0.4
2018 Edmonds EC, Weigand AJ, Thomas KR, Eppig J, Delano-Wood L, Galasko DR, Salmon DP, Bondi MW. Increasing Inaccuracy of Self-Reported Subjective Cognitive Complaints Over 24 Months in Empirically Derived Subtypes of Mild Cognitive Impairment. Journal of the International Neuropsychological Society : Jins. 24: 842-853. PMID 30278855 DOI: 10.1017/S1355617718000486  0.52
2018 Prots I, Grosch J, Brazdis RM, Simmnacher K, Veber V, Havlicek S, Hannappel C, Krach F, Krumbiegel M, Schütz O, Reis A, Wrasidlo W, Galasko DR, Groemer TW, Masliah E, et al. α-Synuclein oligomers induce early axonal dysfunction in human iPSC-based models of synucleinopathies. Proceedings of the National Academy of Sciences of the United States of America. PMID 29991596 DOI: 10.1073/pnas.1713129115  0.4
2018 Zlatar ZZ, Muniz MC, Espinoza S, Gratianne R, Gollan TH, Galasko D, Salmon DP. Subjective Cognitive Decline, Objective Cognition, and Depression in Older Hispanics Screened for Memory Impairment. Journal of Alzheimer's Disease : Jad. PMID 29689718 DOI: 10.3233/JAD-170865  0.52
2018 Wang H, Stewart T, Toledo JB, Ginghina C, Tang L, Atik A, Aro P, Shaw LM, Trojanowski JQ, Galasko DR, Edland S, Jensen PH, Shi M, Zhang J. A Longitudinal Study of Total and Phosphorylated α-Synuclein with Other Biomarkers in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment. Journal of Alzheimer's Disease : Jad. 61: 1541-1553. PMID 29376878 DOI: 10.3233/JAD-171013  0.32
2018 Sundermann EE, Edmonds EC, Delano-Wood L, Galasko DR, Salmon DP, Rubin LH, Bondi MW. Sex Influences the Accuracy of Subjective Memory Complaint Reporting in Older Adults. Journal of Alzheimer's Disease : Jad. 61: 1163-1178. PMID 29332038 DOI: 10.3233/JAD-170425  0.52
2018 Edmonds EC, Ard MC, Edland SD, Galasko DR, Salmon DP, Bondi MW. Unmasking the benefits of donepezil via psychometrically precise identification of mild cognitive impairment: A secondary analysis of the ADCS vitamin E and donepezil in MCI study. Alzheimer's & Dementia (New York, N. Y.). 4: 11-18. PMID 29296659 DOI: 10.1016/j.trci.2017.11.001  0.52
2017 Minakaki G, Menges S, Kittel A, Emmanouilidou E, Schaeffner I, Barkovits K, Bergmann A, Rockenstein E, Adame A, Marxreiter F, Mollenhauer B, Galasko D, Buzás EI, Schlötzer-Schrehardt U, Marcus K, et al. Autophagy inhibition promotes SNCA/alpha-synuclein release and transfer via extracellular vesicles with a hybrid autophagosome-exosome-like phenotype. Autophagy. 1-61. PMID 29198173 DOI: 10.1080/15548627.2017.1395992  0.4
2017 Jacobs DM, Ard MC, Salmon DP, Galasko DR, Bondi MW, Edland SD. Potential implications of practice effects in Alzheimer's disease prevention trials. Alzheimer's & Dementia (New York, N. Y.). 3: 531-535. PMID 29124111 DOI: 10.1016/j.trci.2017.08.010  0.52
2017 Sims R, van der Lee SJ, Naj AC, Bellenguez C, Badarinarayan N, Jakobsdottir J, Kunkle BW, Boland A, Raybould R, Bis JC, Martin ER, Grenier-Boley B, Heilmann-Heimbach S, Chouraki V, Kuzma AB, ... ... Galasko DR, et al. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics. PMID 28714976 DOI: 10.1038/ng.3916  0.32
2017 McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, Aarsland D, Galvin J, Attems J, Ballard CG, Bayston A, Beach TG, Blanc F, Bohnen N, Bonanni L, ... ... Galasko D, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. PMID 28592453 DOI: 10.1212/WNL.0000000000004058  0.52
2017 Xiao MF, Xu D, Craig MT, Pelkey KA, Chien CC, Shi Y, Zhang J, Resnick S, Pletnikova O, Salmon D, Brewer J, Edland S, Wegiel J, Tycko B, Savonenko A, ... ... Galasko D, et al. NPTX2 and cognitive dysfunction in Alzheimer's Disease. Elife. 6. PMID 28440221 DOI: 10.7554/eLife.23798  0.32
2017 Zlatar ZZ, Muniz M, Galasko D, Salmon DP. Subjective Cognitive Decline Correlates With Depression Symptoms and Not With Concurrent Objective Cognition in a Clinic-Based Sample of Older Adults. The Journals of Gerontology. Series B, Psychological Sciences and Social Sciences. PMID 28329816 DOI: 10.1093/geronb/gbw207  0.52
2016 Adamowicz DH, Roy S, Salmon DP, Galasko DR, Hansen LA, Masliah E, Gage FH. Hippocampal α-Synuclein in Dementia with Lewy Bodies Contributes to Memory Impairment and is Consistent with Spread of Pathology. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. PMID 28039370 DOI: 10.1523/JNEUROSCI.3047-16.2016  0.52
2016 Peavy GM, Edland SD, Toole BM, Hansen LA, Galasko DR, Mayo AM. Phenotypic differences based on staging of Alzheimer's neuropathology in autopsy-confirmed dementia with Lewy bodies. Parkinsonism & Related Disorders. PMID 27475955 DOI: 10.1016/j.parkreldis.2016.07.008  0.4
2016 Winston CN, Goetzl EJ, Akers JC, Carter BS, Rockenstein EM, Galasko D, Masliah E, Rissman RA. Prediction of conversion from mild cognitive impairment to dementia with neuronally derived blood exosome protein profile. Alzheimer's & Dementia (Amsterdam, Netherlands). 3: 63-72. PMID 27408937 DOI: 10.1016/j.dadm.2016.04.001  0.4
2016 Mitolo M, Hamilton JM, Landy KM, Hansen LA, Galasko D, Pazzaglia F, Salmon DP. Visual Perceptual Organization Ability in Autopsy-Verified Dementia with Lewy Bodies and Alzheimer's Disease. Journal of the International Neuropsychological Society : Jins. 1-11. PMID 27221597 DOI: 10.1017/S1355617716000436  0.36
2016 Edmonds EC, Delano-Wood L, Jak AJ, Galasko DR, Salmon DP, Bondi MW. "Missed" Mild Cognitive Impairment: High False-Negative Error Rate Based on Conventional Diagnostic Criteria. Journal of Alzheimer's Disease : Jad. PMID 27031477 DOI: 10.3233/JAD-150986  0.36
2016 Kang JH, Mollenhauer B, Coffey CS, Toledo JB, Weintraub D, Galasko DR, Irwin DJ, Van Deerlin V, Chen-Plotkin AS, Caspell-Garcia C, Waligórska T, Taylor P, Shah N, Pan S, Zero P, et al. CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study. Acta Neuropathologica. PMID 27021906 DOI: 10.1007/s00401-016-1552-2  0.36
2016 Su Y, Blazey TM, Owen CJ, Christensen JJ, Friedrichsen K, Joseph-Mathurin N, Wang Q, Hornbeck RC, Ances BM, Snyder AZ, Cash LA, Koeppe RA, Klunk WE, Galasko D, Brickman AM, et al. Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group. Plos One. 11: e0152082. PMID 27010959 DOI: 10.1371/journal.pone.0152082  0.36
2015 Edmonds EC, Delano-Wood L, Galasko DR, Salmon DP, Bondi MW. Subtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer's Disease. Journal of Alzheimer's Disease : Jad. 47: 231-42. PMID 26402771 DOI: 10.3233/JAD-150128  0.36
2015 Li G, Xiong K, Korff A, Pan C, Quinn JF, Galasko DR, Liu C, Montine TJ, Peskind ER, Zhang J. Increased CSF E-Selectin in Clinical Alzheimer's Disease without Altered CSF Aβ42 and Tau. Journal of Alzheimer's Disease : Jad. 47: 883-7. PMID 26401768 DOI: 10.3233/JAD-150420  0.36
2015 Landy KM, Salmon DP, Galasko D, Filoteo JV, Festa EK, Heindel WC, Hansen LA, Hamilton JM. Motion discrimination in dementia with Lewy bodies and Alzheimer disease. Neurology. PMID 26400581 DOI: 10.1212/WNL.0000000000002028  0.36
2015 Ling IF, Golde TE, Galasko DR, Koo EH. Modulation of Aβ42 in vivo by γ-secretase modulator in primates and humans. Alzheimer's Research & Therapy. 7: 55. PMID 26244059 DOI: 10.1186/s13195-015-0137-y  0.52
2015 Yang Y, Keene CD, Peskind ER, Galasko DR, Hu SC, Cudaback E, Wilson AM, Li G, Yu CE, Montine KS, Zhang J, Baird GS, Hyman BT, Montine TJ. Cerebrospinal Fluid Particles in Alzheimer Disease and Parkinson Disease. Journal of Neuropathology and Experimental Neurology. 74: 672-87. PMID 26083568 DOI: 10.1097/NEN.0000000000000207  0.52
2015 Mukherjee S, Walter S, Kauwe JS, Saykin AJ, Bennett DA, Larson EB, Crane PK, Glymour MM. Genetically predicted body mass index and Alzheimer's disease-related phenotypes in three large samples: Mendelian randomization analyses. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 26079416 DOI: 10.1016/j.jalz.2015.05.015  0.36
2015 Nation DA, Edmonds EC, Bangen KJ, Delano-Wood L, Scanlon BK, Han SD, Edland SD, Salmon DP, Galasko DR, Bondi MW. Pulse pressure in relation to tau-mediated neurodegeneration, cerebral amyloidosis, and progression to dementia in very old adults. Jama Neurology. 72: 546-53. PMID 25822631 DOI: 10.1001/jamaneurol.2014.4477  0.36
2015 Tinklenberg JR, Kraemer HC, Yaffe K, O'Hara R, Ringman JM, Ashford JW, Yesavage JA, Taylor JL. Donepezil treatment in ethnically diverse patients with Alzheimer disease. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 23: 384-90. PMID 25747405 DOI: 10.1016/j.jagp.2014.09.007  0.52
2015 Weintraub D, Simuni T, Caspell-Garcia C, Coffey C, Lasch S, Siderowf A, Aarsland D, Barone P, Burn D, Chahine LM, Eberling J, Espay AJ, Foster ED, Leverenz JB, Litvan I, et al. Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 30: 919-27. PMID 25737166 DOI: 10.1002/mds.26170  0.52
2015 Pan C, Korff A, Galasko D, Ginghina C, Peskind E, Li G, Quinn J, Montine TJ, Cain K, Shi M, Zhang J. Diagnostic Values of Cerebrospinal Fluid T-Tau and Aβ₄₂ using Meso Scale Discovery Assays for Alzheimer's Disease. Journal of Alzheimer's Disease : Jad. 45: 709-19. PMID 25613100 DOI: 10.3233/JAD-143099  0.52
2015 Shi M, Movius J, Dator R, Aro P, Zhao Y, Pan C, Lin X, Bammler TK, Stewart T, Zabetian CP, Peskind ER, Hu SC, Quinn JF, Galasko DR, Zhang J. Cerebrospinal fluid peptides as potential Parkinson disease biomarkers: a staged pipeline for discovery and validation. Molecular & Cellular Proteomics : McP. 14: 544-55. PMID 25556233 DOI: 10.1074/mcp.M114.040576  0.52
2015 Wang LS, Naj AC, Graham RR, Crane PK, Kunkle BW, Cruchaga C, Murcia JD, Cannon-Albright L, Baldwin CT, Zetterberg H, Blennow K, Kukull WA, Faber KM, Schupf N, Norton MC, ... ... Galasko DR, et al. Rarity of the Alzheimer disease-protective APP A673T variant in the United States. Jama Neurology. 72: 209-16. PMID 25531812 DOI: 10.1001/jamaneurol.2014.2157  0.52
2015 Bangen KJ, Nation DA, Delano-Wood L, Weissberger GH, Hansen LA, Galasko DR, Salmon DP, Bondi MW. Aggregate effects of vascular risk factors on cerebrovascular changes in autopsy-confirmed Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 11: 394-403.e1. PMID 25022538 DOI: 10.1016/j.jalz.2013.12.025  0.36
2015 Edmonds EC, Delano-Wood L, Clark LR, Jak AJ, Nation DA, McDonald CR, Libon DJ, Au R, Galasko D, Salmon DP, Bondi MW. Susceptibility of the conventional criteria for mild cognitive impairment to false-positive diagnostic errors. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 11: 415-24. PMID 24857234 DOI: 10.1016/j.jalz.2014.03.005  0.52
2015 Galasko D. Expanding the repertoire of biomarkers for Alzheimer's disease: Targeted and non-targeted approaches Frontiers in Neurology. 6. DOI: 10.3389/fneur.2015.00256  0.52
2015 MacKin RS, Insel P, Zhang J, Mohlenhoff B, Galasko D, Weiner M, Mattsson N. Cerebrospinal fluid α-synuclein and lewy body-like symptoms in normal controls, mild cognitive impairment, and Alzheimer's disease Journal of Alzheimer's Disease. 43: 1007-1016. DOI: 10.3233/JAD-141287  0.52
2015 Breitner JCS, Galasko D. Encouraging trends toward reduced risk of Alzheimer disease Neurology: Clinical Practice. 5: 190-192. DOI: 10.1212/CPJ.0000000000000110  0.52
2015 Salmon DP, Heindel WC, Hamilton JM, Vincent Filoteo J, Cidambi V, Hansen LA, Masliah E, Galasko D. Recognition memory span in autopsy-confirmed Dementia with Lewy Bodies and Alzheimer's Disease Neuropsychologia. 75: 548-555. DOI: 10.1016/j.neuropsychologia.2015.07.014  0.52
2014 Donohue MC, Moghadam SH, Roe AD, Sun CK, Edland SD, Thomas RG, Petersen RC, Sano M, Galasko D, Aisen PS, Rissman RA. Longitudinal plasma amyloid beta in Alzheimer's disease clinical trials. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 25301682 DOI: 10.1016/j.jalz.2014.07.156  0.52
2014 Edmonds EC, Delano-Wood L, Galasko DR, Salmon DP, Bondi MW. Subjective cognitive complaints contribute to misdiagnosis of mild cognitive impairment. Journal of the International Neuropsychological Society : Jins. 20: 836-47. PMID 25156329 DOI: 10.1017/S135561771400068X  0.52
2014 Peskind ER, Li G, Shofer JB, Millard SP, Leverenz JB, Yu CE, Raskind MA, Quinn JF, Galasko DR, Montine TJ. Influence of lifestyle modifications on age-related free radical injury to brain. Jama Neurology. 71: 1150-4. PMID 25048271 DOI: 10.1001/jamaneurol.2014.1428  0.52
2014 Shi M, Liu C, Cook TJ, Bullock KM, Zhao Y, Ginghina C, Li Y, Aro P, Dator R, He C, Hipp MJ, Zabetian CP, Peskind ER, Hu SC, Quinn JF, ... Galasko DR, et al. Plasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson's disease. Acta Neuropathologica. 128: 639-50. PMID 24997849 DOI: 10.1007/s00401-014-1314-y  0.36
2014 Pan C, Zhou Y, Dator R, Ginghina C, Zhao Y, Movius J, Peskind E, Zabetian CP, Quinn J, Galasko D, Stewart T, Shi M, Zhang J. Targeted discovery and validation of plasma biomarkers of Parkinson's disease. Journal of Proteome Research. 13: 4535-45. PMID 24853996 DOI: 10.1021/pr500421v  0.52
2014 Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, DeKosky ST, Gauthier S, Selkoe D, Bateman R, Cappa S, Crutch S, Engelborghs S, Frisoni GB, Fox NC, ... Galasko D, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. The Lancet. Neurology. 13: 614-29. PMID 24849862 DOI: 10.1016/S1474-4422(14)70090-0  0.52
2014 Bondi MW, Edmonds EC, Jak AJ, Clark LR, Delano-Wood L, McDonald CR, Nation DA, Libon DJ, Au R, Galasko D, Salmon DP. Neuropsychological criteria for mild cognitive impairment improves diagnostic precision, biomarker associations, and progression rates. Journal of Alzheimer's Disease : Jad. 42: 275-89. PMID 24844687 DOI: 10.3233/JAD-140276  0.36
2014 Zhu CW, Sano M, Ferris SH, Whitehouse PJ, Patterson MB, Galasko D, Schneider LS, Aisen PS. Alzheimer's Disease Cooperative Study Prevention Instrument Project assessing resource use and volunteer and paid work in healthy elders: a longitudinal study. Journal of the American Geriatrics Society. 62: 985-8. PMID 24828933 DOI: 10.1111/jgs.12816  0.36
2014 Li G, Millard SP, Peskind ER, Zhang J, Yu CE, Leverenz JB, Mayer C, Shofer JS, Raskind MA, Quinn JF, Galasko DR, Montine TJ. Cross-sectional and longitudinal relationships between cerebrospinal fluid biomarkers and cognitive function in people without cognitive impairment from across the adult life span. Jama Neurology. 71: 742-51. PMID 24756381 DOI: 10.1001/jamaneurol.2014.445  0.52
2014 Siderowf A, Pontecorvo MJ, Shill HA, Mintun MA, Arora A, Joshi AD, Lu M, Adler CH, Galasko D, Liebsack C, Skovronsky DM, Sabbagh MN. PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer's disease and Lewy body disorders. Bmc Neurology. 14: 79. PMID 24716655 DOI: 10.1186/1471-2377-14-79  0.52
2014 Galasko D, Bell J, Mancuso JY, Kupiec JW, Sabbagh MN, van Dyck C, Thomas RG, Aisen PS. Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer disease. Neurology. 82: 1536-42. PMID 24696507 DOI: 10.1212/WNL.0000000000000364  0.52
2014 Gallagher MD, Suh E, Grossman M, Elman L, McCluskey L, Van Swieten JC, Al-Sarraj S, Neumann M, Gelpi E, Ghetti B, Rohrer JD, Halliday G, Van Broeckhoven C, Seilhean D, Shaw PJ, ... ... Galasko D, et al. TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions. Acta Neuropathologica. 127: 407-18. PMID 24442578 DOI: 10.1007/s00401-013-1239-x  0.52
2014 Burstein AH, Grimes I, Galasko DR, Aisen PS, Sabbagh M, Mjalli AM. Effect of TTP488 in patients with mild to moderate Alzheimer's disease. Bmc Neurology. 14: 12. PMID 24423155 DOI: 10.1186/1471-2377-14-12  0.52
2014 Ubhi K, Rockenstein E, Kragh C, Inglis C, Spencer B, Michael S, Mante M, Adame A, Galasko D, Masliah E. Widespread microRNA dysregulation in multiple system atrophy - disease-related alteration in miR-96. The European Journal of Neuroscience. 39: 1026-41. PMID 24304186 DOI: 10.1111/ejn.12444  0.52
2014 Mitolo M, Salmon DP, Gardini S, Galasko D, Grossi E, Caffarra P. The new Qualitative Scoring MMSE Pentagon Test (QSPT) as a valid screening tool between autopsy-confirmed dementia with Lewy bodies and Alzheimer's disease. Journal of Alzheimer's Disease : Jad. 39: 823-32. PMID 24284368 DOI: 10.3233/JAD-131403  0.52
2014 Lineweaver TT, Bondi MW, Galasko D, Salmon DP. Effect of knowledge of APOE genotype on subjective and objective memory performance in healthy older adults. The American Journal of Psychiatry. 171: 201-8. PMID 24170170 DOI: 10.1176/appi.ajp.2013.12121590  0.52
2014 Millard SP, Lutz F, Li G, Galasko DR, Farlow MR, Quinn JF, Kaye JA, Leverenz JB, Tsuang D, Yu CE, Peskind ER, Bekris LM. Association of cerebrospinal fluid Aβ42 with A2M gene in cognitively normal subjects. Neurobiology of Aging. 35: 357-64. PMID 24011543 DOI: 10.1016/j.neurobiolaging.2013.07.027  0.36
2014 Hamilton JM, Salmon DP, Raman R, Hansen LA, Masliah E, Peavy GM, Galasko D. Accounting for functional loss in Alzheimer's disease and dementia with Lewy bodies: beyond cognition. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 10: 171-8. PMID 23850331 DOI: 10.1016/j.jalz.2013.04.003  0.52
2013 Mattsson N, Insel P, Tosun D, Zhang J, Jack CR, Galasko D, Weiner M. Effects of baseline CSF α-synuclein on regional brain atrophy rates in healthy elders, mild cognitive impairment and Alzheimer's disease. Plos One. 8: e85443. PMID 24392009 DOI: 10.1371/journal.pone.0085443  0.52
2013 Nation DA, Edland SD, Bondi MW, Salmon DP, Delano-Wood L, Peskind ER, Quinn JF, Galasko DR. Pulse pressure is associated with Alzheimer biomarkers in cognitively normal older adults. Neurology. 81: 2024-7. PMID 24225352 DOI: 10.1212/01.wnl.0000436935.47657.78  0.52
2013 Olichney JM, Pak J, Salmon DP, Yang JC, Gahagan T, Nowacki R, Hansen L, Galasko D, Kutas M, Iragui-Madoz VJ. Abnormal P600 word repetition effect in elderly persons with preclinical Alzheimer's disease. Cognitive Neuroscience. 4: 143-51. PMID 24090465 DOI: 10.1080/17588928.2013.838945  0.52
2013 Masliah E, Dumaop W, Galasko D, Desplats P. Distinctive patterns of DNA methylation associated with Parkinson disease: identification of concordant epigenetic changes in brain and peripheral blood leukocytes. Epigenetics : Official Journal of the Dna Methylation Society. 8: 1030-8. PMID 23907097 DOI: 10.4161/epi.25865  0.52
2013 Pirogovsky E, Holden HM, Jenkins C, Peavy GM, Salmon DP, Galasko DR, Gilbert PE. Temporal sequence learning in healthy aging and amnestic mild cognitive impairment. Experimental Aging Research. 39: 371-81. PMID 23875836 DOI: 10.1080/0361073X.2013.808122  0.36
2013 Galasko D, Golde TE, Scheltens P. Progress in Alzheimer's disease research circa 2013: Is the glass half empty or half full? Alzheimer's Research & Therapy. 5: 26. PMID 23731836 DOI: 10.1186/alzrt180  0.52
2013 Wang LY, Murphy RR, Hanscom B, Li G, Millard SP, Petrie EC, Galasko DR, Sikkema C, Raskind MA, Wilkinson CW, Peskind ER. Cerebrospinal fluid norepinephrine and cognition in subjects across the adult age span. Neurobiology of Aging. 34: 2287-92. PMID 23639207 DOI: 10.1016/j.neurobiolaging.2013.04.007  0.52
2013 Lamarre AK, Rascovsky K, Bostrom A, Toofanian P, Wilkins S, Sha SJ, Perry DC, Miller ZA, Naasan G, Laforce R, Hagen J, Takada LT, Tartaglia MC, Kang G, Galasko D, et al. Interrater reliability of the new criteria for behavioral variant frontotemporal dementia. Neurology. 80: 1973-7. PMID 23635967 DOI: 10.1212/WNL.0b013e318293e368  0.52
2013 Dombroski BA, Galasko DR, Mata IF, Zabetian CP, Craig UK, Garruto RM, Oyanagi K, Schellenberg GD. C9orf72 hexanucleotide repeat expansion and Guam amyotrophic lateral sclerosis-Parkinsonism-dementia complex. Jama Neurology. 70: 742-5. PMID 23588498 DOI: 10.1001/jamaneurol.2013.1817  0.52
2013 Peavy GM, Salmon DP, Edland SD, Tam S, Hansen LA, Masliah E, Galasko D, Hamilton JM. Neuropsychiatric features of frontal lobe dysfunction in autopsy-confirmed patients with lewy bodies and "pure" Alzheimer disease. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 21: 509-19. PMID 23567425 DOI: 10.1016/j.jagp.2012.10.022  0.52
2013 Cruchaga C, Kauwe JS, Harari O, Jin SC, Cai Y, Karch CM, Benitez BA, Jeng AT, Skorupa T, Carrell D, Bertelsen S, Bailey M, McKean D, Shulman JM, De Jager PL, ... ... Galasko D, et al. GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease. Neuron. 78: 256-68. PMID 23562540 DOI: 10.1016/j.neuron.2013.02.026  0.52
2013 Galasko D. The diagnostic evaluation of a patient with dementia Continuum Lifelong Learning in Neurology. 19: 397-410. PMID 23558485 DOI: 10.1212/01.CON.0000429176.37224.58  0.52
2013 Galasko D, Golde TE. Biomarkers for Alzheimer's disease in plasma, serum and blood - conceptual and practical problems. Alzheimer's Research & Therapy. 5: 10. PMID 23470193 DOI: 10.1186/alzrt164  0.52
2013 Tsuang D, Leverenz JB, Lopez OL, Hamilton RL, Bennett DA, Schneider JA, Buchman AS, Larson EB, Crane PK, Kaye JA, Kramer P, Woltjer R, Trojanowski JQ, Weintraub D, Chen-Plotkin AS, ... ... Galasko D, et al. APOE ε4 increases risk for dementia in pure synucleinopathies. Jama Neurology. 70: 223-8. PMID 23407718 DOI: 10.1001/jamaneurol.2013.600  0.52
2013 Galasko DR, Aisen P. Antioxidants for Alzheimer disease-reply. Jama Neurology. 70: 270-1. PMID 23400724 DOI: 10.1001/jamaneurol.2013.935  0.52
2013 Winchester J, Dick MB, Gillen D, Reed B, Miller B, Tinklenberg J, Mungas D, Chui H, Galasko D, Hewett L, Cotman CW. Walking stabilizes cognitive functioning in Alzheimer's disease (AD) across one year. Archives of Gerontology and Geriatrics. 56: 96-103. PMID 22959822 DOI: 10.1016/j.archger.2012.06.016  0.52
2013 Ard MC, Galasko DR, Edland SD. Improved statistical power of Alzheimer clinical trials by item-response theory: proof of concept by application to the activities of daily living scale. Alzheimer Disease and Associated Disorders. 27: 187-91. PMID 22874658 DOI: 10.1097/WAD.0b013e318265bcc1  0.36
2012 Tsuang D, Leverenz JB, Lopez OL, Hamilton RL, Bennett DA, Schneider JA, Buchman AS, Larson EB, Crane PK, Kaye JA, Kramer P, Woltjer R, Kukull W, Nelson PT, Jicha GA, ... ... Galasko D, et al. GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology. Neurology. 79: 1944-50. PMID 23035075 DOI: 10.1212/WNL.0b013e3182735e9a  0.52
2012 Bekris LM, Millard S, Lutz F, Li G, Galasko DR, Farlow MR, Quinn JF, Kaye JA, Leverenz JB, Tsuang DW, Yu CE, Peskind ER. Tau phosphorylation pathway genes and cerebrospinal fluid tau levels in Alzheimer's disease. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics. 159: 874-83. PMID 22927204 DOI: 10.1002/ajmg.b.32094  0.52
2012 Pillai JA, McEvoy LK, Hagler DJ, Holland D, Dale AM, Salmon DP, Galasko D, Fennema-Notestine C. Higher education is not associated with greater cortical thickness in brain areas related to literacy or intelligence in normal aging or mild cognitive impairment. Journal of Clinical and Experimental Neuropsychology. 34: 925-35. PMID 22905705 DOI: 10.1080/13803395.2012.702733  0.52
2012 Wagner SL, Tanzi RE, Mobley WC, Galasko D. Potential use of γ-secretase modulators in the treatment of Alzheimer disease. Archives of Neurology. 69: 1255-8. PMID 22801784 DOI: 10.1001/archneurol.2012.540  0.52
2012 Galasko D, Golde T, Wilcock G. Recent Alzheimer's disease research highlights. Alzheimer's Research & Therapy. 4: 14. PMID 22594696 DOI: 10.1186/alzrt117  0.52
2012 Bekris LM, Lutz F, Li G, Galasko DR, Farlow MR, Quinn JF, Kaye JA, Leverenz JB, Tsuang DW, Montine TJ, Peskind ER, Yu CE. ADAM10 expression and promoter haplotype in Alzheimer's disease. Neurobiology of Aging. 33: 2229.e1-2229.e9. PMID 22572541 DOI: 10.1016/j.neurobiolaging.2012.03.013  0.52
2012 Coppola G, Chinnathambi S, Lee JJ, Dombroski BA, Baker MC, Soto-Ortolaza AI, Lee SE, Klein E, Huang AY, Sears R, Lane JR, Karydas AM, Kenet RO, Biernat J, Wang LS, ... ... Galasko DR, et al. Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. Human Molecular Genetics. 21: 3500-12. PMID 22556362 DOI: 10.1093/hmg/dds161  0.4
2012 Nation DA, Delano-Wood L, Bangen KJ, Wierenga CE, Jak AJ, Hansen LA, Galasko DR, Salmon DP, Bondi MW. Antemortem pulse pressure elevation predicts cerebrovascular disease in autopsy-confirmed Alzheimer's disease. Journal of Alzheimer's Disease : Jad. 30: 595-603. PMID 22451309 DOI: 10.3233/JAD-2012-111697  0.36
2012 Galasko DR, Peskind E, Clark CM, Quinn JF, Ringman JM, Jicha GA, Cotman C, Cottrell B, Montine TJ, Thomas RG, Aisen P. Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. Archives of Neurology. 69: 836-41. PMID 22431837 DOI: 10.1001/archneurol.2012.85  0.52
2012 Irizarry MC, Jin S, He F, Emond JA, Raman R, Thomas RG, Sano M, Quinn JF, Tariot PN, Galasko DR, Ishihara LS, Weil JG, Aisen PS. Incidence of new-onset seizures in mild to moderate Alzheimer disease. Archives of Neurology. 69: 368-72. PMID 22410444 DOI: 10.1001/archneurol.2011.830  0.52
2012 Wang Y, Shi M, Chung KA, Zabetian CP, Leverenz JB, Berg D, Srulijes K, Trojanowski JQ, Lee VM, Siderowf AD, Hurtig H, Litvan I, Schiess MC, Peskind ER, Masuda M, ... ... Galasko D, et al. Phosphorylated α-synuclein in Parkinson's disease. Science Translational Medicine. 4: 121ra20. PMID 22344688 DOI: 10.1126/scitranslmed.3002566  0.52
2012 Mandler M, Rockenstein E, Ubhi K, Hansen L, Adame A, Michael S, Galasko D, Santic R, Mattner F, Masliah E. Detection of peri-synaptic amyloid-β pyroglutamate aggregates in early stages of Alzheimer's disease and in AβPP transgenic mice using a novel monoclonal antibody. Journal of Alzheimer's Disease : Jad. 28: 783-94. PMID 22064070 DOI: 10.3233/JAD-2011-111208  0.52
2012 Peavy GM, Jacobson MW, Salmon DP, Gamst AC, Patterson TL, Goldman S, Mills PJ, Khandrika S, Galasko D. The influence of chronic stress on dementia-related diagnostic change in older adults. Alzheimer Disease and Associated Disorders. 26: 260-6. PMID 22037597 DOI: 10.1097/WAD.0b013e3182389a9c  0.52
2012 Hamilton JM, Landy KM, Salmon DP, Hansen LA, Masliah E, Galasko D. Early visuospatial deficits predict the occurrence of visual hallucinations in autopsy-confirmed dementia with Lewy bodies. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 20: 773-81. PMID 21997600 DOI: 10.1097/JGP.0b013e31823033bc  0.52
2011 Gollan TH, Salmon DP, Montoya RI, Galasko DR. Degree of bilingualism predicts age of diagnosis of Alzheimer's disease in low-education but not in highly educated Hispanics. Neuropsychologia. 49: 3826-30. PMID 22001315 DOI: 10.1016/j.neuropsychologia.2011.09.041  0.52
2011 Edland SD, Galasko DR. Fractional synthesis and clearance rates for amyloid β. Nature Medicine. 17: 1178-9; author reply. PMID 21988985 DOI: 10.1038/nm.2495  0.52
2011 Marek K, Jennings D, Lasch S, Siderowf A, Tanner C, Simuni T, Coffey C, Kieburtz K, Flagg E, Chowdhury S, Poewe W, Mollenhauer B, Sherer T, Frasier M, Meunier C, ... ... Galasko D, et al. The Parkinson Progression Marker Initiative (PPMI) Progress in Neurobiology. 95: 629-635. PMID 21930184 DOI: 10.1016/j.pneurobio.2011.09.005  0.52
2011 Villeda SA, Luo J, Mosher KI, Zou B, Britschgi M, Bieri G, Stan TM, Fainberg N, Ding Z, Eggel A, Lucin KM, Czirr E, Park JS, Couillard-Després S, Aigner L, ... ... Galasko DR, et al. The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature. 477: 90-4. PMID 21886162 DOI: 10.1038/nature10357  0.52
2011 Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, van Swieten JC, Seelaar H, Dopper EG, Onyike CU, Hillis AE, Josephs KA, Boeve BF, Kertesz A, Seeley WW, ... ... Galasko D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain : a Journal of Neurology. 134: 2456-77. PMID 21810890 DOI: 10.1093/brain/awr179  0.52
2011 Sano M, Bell KL, Galasko D, Galvin JE, Thomas RG, van Dyck CH, Aisen PS. A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology. 77: 556-63. PMID 21795660 DOI: 10.1212/WNL.0b013e318228bf11  0.52
2011 Mattsson N, Andreasson U, Persson S, Arai H, Batish SD, Bernardini S, Bocchio-Chiavetto L, Blankenstein MA, Carrillo MC, Chalbot S, Coart E, Chiasserini D, Cutler N, Dahlfors G, Duller S, ... ... Galasko D, et al. The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 7: 386-395.e6. PMID 21784349 DOI: 10.1016/j.jalz.2011.05.2243  0.52
2011 Britschgi M, Rufibach K, Huang SL, Clark CM, Kaye JA, Li G, Peskind ER, Quinn JF, Galasko DR, Wyss-Coray T. Modeling of pathological traits in Alzheimer's disease based on systemic extracellular signaling proteome. Molecular & Cellular Proteomics : McP. 10: M111.008862. PMID 21742799 DOI: 10.1074/mcp.M111.008862  0.52
2011 Höglinger GU, Melhem NM, Dickson DW, Sleiman PM, Wang LS, Klei L, Rademakers R, de Silva R, Litvan I, Riley DE, van Swieten JC, Heutink P, Wszolek ZK, Uitti RJ, Vandrovcova J, et al. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nature Genetics. 43: 699-705. PMID 21685912 DOI: 10.1038/ng.859  0.52
2011 Golde TE, Lamb BT, Galasko D. Right sizing funding for Alzheimer's disease. Alzheimer's Research & Therapy. 3: 17. PMID 21554753 DOI: 10.1186/alzrt76  0.52
2011 Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buros J, Gallins PJ, Buxbaum JD, Jarvik GP, Crane PK, Larson EB, Bird TD, Boeve BF, Graff-Radford NR, De Jager PL, ... ... Galasko DR, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nature Genetics. 43: 436-41. PMID 21460841 DOI: 10.1038/ng.801  0.52
2011 Wang Y, Hancock AM, Bradner J, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Kim HM, Leverenz JB, Montine TJ, Ginghina C, Edwards KL, Snapinn KW, et al. Complement 3 and factor h in human cerebrospinal fluid in Parkinson's disease, Alzheimer's disease, and multiple-system atrophy. The American Journal of Pathology. 178: 1509-16. PMID 21435440 DOI: 10.1016/j.ajpath.2011.01.006  0.52
2011 Rafii M, Taylor C, Coutinho A, Kim K, Galasko D. Comparison of the memory performance index with standard neuropsychological measures of cognition American Journal of Alzheimer's Disease and Other Dementias. 26: 235-239. PMID 21406427 DOI: 10.1177/1533317511402316  0.52
2011 Shi M, Bradner J, Hancock AM, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Kim HM, Leverenz JB, Montine TJ, Ginghina C, Kang UJ, Cain KC, et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Annals of Neurology. 69: 570-80. PMID 21400565 DOI: 10.1002/ana.22311  0.52
2011 Chang YL, Bondi MW, McEvoy LK, Fennema-Notestine C, Salmon DP, Galasko D, Hagler DJ, Dale AM. Global clinical dementia rating of 0.5 in MCI masks variability related to level of function. Neurology. 76: 652-9. PMID 21321338 DOI: 10.1212/WNL.0b013e31820ce6a5  0.52
2011 Perrin RJ, Craig-Schapiro R, Malone JP, Shah AR, Gilmore P, Davis AE, Roe CM, Peskind ER, Li G, Galasko DR, Clark CM, Quinn JF, Kaye JA, Morris JC, Holtzman DM, et al. Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease. Plos One. 6: e16032. PMID 21264269 DOI: 10.1371/journal.pone.0016032  0.52
2011 Bekris LM, Galloway NM, Millard S, Lockhart D, Li G, Galasko DR, Farlow MR, Clark CM, Quinn JF, Kaye JA, Schellenberg GD, Leverenz JB, Seubert P, Tsuang DW, Peskind ER, et al. Amyloid precursor protein (APP) processing genes and cerebrospinal fluid APP cleavage product levels in Alzheimer's disease. Neurobiology of Aging. 32: 556.e13-23. PMID 21196064 DOI: 10.1016/j.neurobiolaging.2010.10.020  0.52
2011 Sabbagh MN, Agro A, Bell J, Aisen PS, Schweizer E, Galasko D. PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease Alzheimer Disease and Associated Disorders. 25: 206-212. PMID 21192237 DOI: 10.1097/WAD.0b013e318204b550  0.52
2011 Montine TJ, Peskind ER, Quinn JF, Wilson AM, Montine KS, Galasko D. Increased cerebrospinal fluid F2-isoprostanes are associated with aging and latent Alzheimer's disease as identified by biomarkers. Neuromolecular Medicine. 13: 37-43. PMID 20632131 DOI: 10.1007/s12017-010-8126-6  0.52
2011 Kramer PL, Xu H, Woltjer RL, Westaway SK, Clark D, Erten-Lyons D, Kaye JA, Welsh-Bohmer KA, Troncoso JC, Markesbery WR, Petersen RC, Turner RS, Kukull WA, Bennett DA, Galasko D, et al. Alzheimer disease pathology in cognitively healthy elderly: a genome-wide study. Neurobiology of Aging. 32: 2113-22. PMID 20452100 DOI: 10.1016/j.neurobiolaging.2010.01.010  0.52
2010 Mata IF, Shi M, Agarwal P, Chung KA, Edwards KL, Factor SA, Galasko DR, Ginghina C, Griffith A, Higgins DS, Kay DM, Kim H, Leverenz JB, Quinn JF, Roberts JW, et al. SNCA variant associated with Parkinson disease and plasma alpha-synuclein level. Archives of Neurology. 67: 1350-6. PMID 21060011 DOI: 10.1001/archneurol.2010.279  0.52
2010 Mortimer JA, Borenstein AR, Ding D, Decarli C, Zhao Q, Copenhaver C, Guo Q, Chu S, Galasko D, Salmon DP, Dai Q, Wu Y, Petersen R, Hong Z. High normal fasting blood glucose is associated with dementia in Chinese elderly. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 6: 440-7. PMID 21044774 DOI: 10.1016/j.jalz.2010.03.017  0.52
2010 Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ, Mintun MA, Peskind ER, Li G, Galasko DR, Clark CM, Quinn JF, D'Angelo G, Malone JP, Townsend RR, et al. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. Biological Psychiatry. 68: 903-12. PMID 21035623 DOI: 10.1016/j.biopsych.2010.08.025  0.52
2010 He J, Iosif AM, Lee DY, Martinez O, Chu S, Carmichael O, Mortimer JA, Zhao Q, Ding D, Guo Q, Galasko D, Salmon DP, Dai Q, Wu Y, Petersen RC, et al. Brain structure and cerebrovascular risk in cognitively impaired patients: Shanghai Community Brain Health Initiative-pilot phase. Archives of Neurology. 67: 1231-7. PMID 20937951 DOI: 10.1001/archneurol.2010.230  0.52
2010 Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, Delacourte A, Frisoni G, Fox NC, Galasko D, Gauthier S, Hampel H, Jicha GA, Meguro K, O'Brien J, et al. Revising the definition of Alzheimer's disease: a new lexicon. The Lancet. Neurology. 9: 1118-27. PMID 20934914 DOI: 10.1016/S1474-4422(10)70223-4  0.52
2010 Pedrosa H, De Sa A, Guerreiro M, Maroco J, Simoes MR, Galasko D, de Mendonca A. Functional evaluation distinguishes MCI patients from healthy elderly people--the ADCS/MCI/ADL scale. The Journal of Nutrition, Health & Aging. 14: 703-9. PMID 20922349 DOI: 10.1007/s12603-010-0102-1  0.52
2010 Cruchaga C, Kauwe JS, Mayo K, Spiegel N, Bertelsen S, Nowotny P, Shah AR, Abraham R, Hollingworth P, Harold D, Owen MM, Williams J, Lovestone S, Peskind ER, Li G, ... ... Galasko D, et al. SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease. Plos Genetics. 6: e1001101. PMID 20862329 DOI: 10.1371/journal.pgen.1001101  0.52
2010 Ubhi K, Peng K, Lessig S, Estrella J, Adame A, Galasko D, Salmon DP, Hansen LA, Kawas CH, Masliah E. Neuropathology of dementia with Lewy bodies in advanced age: a comparison with Alzheimer disease. Neuroscience Letters. 485: 222-7. PMID 20849919 DOI: 10.1016/j.neulet.2010.09.016  0.52
2010 Montine TJ, Shi M, Quinn JF, Peskind ER, Craft S, Ginghina C, Chung KA, Kim H, Galasko DR, Jankovic J, Zabetian CP, Leverenz JB, Zhang J. CSF Aβ(42) and tau in Parkinson's disease with cognitive impairment. Movement Disorders : Official Journal of the Movement Disorder Society. 25: 2682-5. PMID 20818673 DOI: 10.1002/mds.23287  0.52
2010 Pham E, Crews L, Ubhi K, Hansen L, Adame A, Cartier A, Salmon D, Galasko D, Michael S, Savas JN, Yates JR, Glabe C, Masliah E. Progressive accumulation of amyloid-beta oligomers in Alzheimer's disease and in amyloid precursor protein transgenic mice is accompanied by selective alterations in synaptic scaffold proteins. The Febs Journal. 277: 3051-67. PMID 20573181 DOI: 10.1111/j.1742-4658.2010.07719.x  0.52
2010 Shi M, Zabetian CP, Hancock AM, Ginghina C, Hong Z, Yearout D, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Leverenz JB, Zhang J. Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. Neuroscience Letters. 480: 78-82. PMID 20540987 DOI: 10.1016/j.neulet.2010.06.009  0.52
2010 Lessig S, Ubhi K, Galasko D, Adame A, Pham E, Remidios K, Chang M, Hansen LA, Masliah E. Reduced hypocretin (orexin) levels in dementia with Lewy bodies. Neuroreport. 21: 756-60. PMID 20531237 DOI: 10.1097/WNR.0b013e32833bfb7c  0.52
2010 Galasko D, Montine TJ. Biomarkers of oxidative damage and inflammation in Alzheimer's disease. Biomarkers in Medicine. 4: 27-36. PMID 20383271 DOI: 10.2217/bmm.09.89  0.52
2010 Crews L, Spencer B, Desplats P, Patrick C, Paulino A, Rockenstein E, Hansen L, Adame A, Galasko D, Masliah E. Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy. Plos One. 5: e9313. PMID 20174468 DOI: 10.1371/journal.pone.0009313  0.52
2010 Hong Z, Shi M, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Leverenz JB, Baird G, Montine TJ, Hancock AM, Hwang H, Pan C, Bradner J, et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain : a Journal of Neurology. 133: 713-26. PMID 20157014 DOI: 10.1093/brain/awq008  0.52
2010 Portelius E, Andreasson U, Ringman JM, Buerger K, Daborg J, Buchhave P, Hansson O, Harmsen A, Gustavsson MK, Hanse E, Galasko D, Hampel H, Blennow K, Zetterberg H. Distinct cerebrospinal fluid amyloid beta peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer's disease. Molecular Neurodegeneration. 5: 2. PMID 20145736 DOI: 10.1186/1750-1326-5-2  0.52
2010 Borenstein AR, Mortimer JA, Ding Ding, Schellenberg GD, DeCarli C, Qianhua Zhao, Copenhaver C, Qihao Guo, Shugang Chu, Galasko D, Salmon DP, Qi Dai, Yougui Wu, Petersen R, Zhen Hong. Effects of apolipoprotein E-epsilon4 and -epsilon2 in amnestic mild cognitive impairment and dementia in Shanghai: SCOBHI-P. American Journal of Alzheimer's Disease and Other Dementias. 25: 233-8. PMID 20142627 DOI: 10.1177/1533317509357736  0.52
2010 Yu CE, Bird TD, Bekris LM, Montine TJ, Leverenz JB, Steinbart E, Galloway NM, Feldman H, Woltjer R, Miller CA, Wood EM, Grossman M, McCluskey L, Clark CM, Neumann M, ... ... Galasko DR, et al. The spectrum of mutations in progranulin: a collaborative study screening 545 cases of neurodegeneration. Archives of Neurology. 67: 161-70. PMID 20142524 DOI: 10.1001/archneurol.2009.328  0.52
2009 Peavy GM, Salmon DP, Jacobson MW, Hervey A, Gamst AC, Wolfson T, Patterson TL, Goldman S, Mills PJ, Khandrika S, Galasko D. Effects of chronic stress on memory decline in cognitively normal and mildly impaired older adults. The American Journal of Psychiatry. 166: 1384-91. PMID 19755573 DOI: 10.1176/appi.ajp.2009.09040461  0.52
2009 Donnelly A, Galasko D, Golde T, Mulvany F, Wilcock G. Welcome to Alzheimer's research & therapy. Alzheimer's Research & Therapy. 1: 1. PMID 19671199 DOI: 10.1186/alzrt1  0.52
2009 Britschgi M, Olin CE, Johns HT, Takeda-Uchimura Y, LeMieux MC, Rufibach K, Rajadas J, Zhang H, Tomooka B, Robinson WH, Clark CM, Fagan AM, Galasko DR, Holtzman DM, Jutel M, et al. Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America. 106: 12145-50. PMID 19581601 DOI: 10.1073/pnas.0904866106  0.52
2009 Sieh W, Choi Y, Chapman NH, Craig UK, Steinbart EJ, Rothstein JH, Oyanagi K, Garruto RM, Bird TD, Galasko DR, Schellenberg GD, Wijsman EM. Identification of novel susceptibility loci for Guam neurodegenerative disease: challenges of genome scans in genetic isolates. Human Molecular Genetics. 18: 3725-38. PMID 19567404 DOI: 10.1093/hmg/ddp300  0.52
2009 Petrie EC, Cross DJ, Galasko D, Schellenberg GD, Raskind MA, Peskind ER, Minoshima S. Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings. Archives of Neurology. 66: 632-7. PMID 19433663 DOI: 10.1001/archneurol.2009.59  0.52
2009 Li G, Peskind ER, Millard SP, Chi P, Sokal I, Yu CE, Bekris LM, Raskind MA, Galasko DR, Montine TJ. Cerebrospinal fluid concentration of brain-derived neurotrophic factor and cognitive function in non-demented subjects. Plos One. 4: e5424. PMID 19412541 DOI: 10.1371/journal.pone.0005424  0.52
2009 Ma QL, Galasko DR, Ringman JM, Vinters HV, Edland SD, Pomakian J, Ubeda OJ, Rosario ER, Teter B, Frautschy SA, Cole GM. Reduction of SorLA/LR11, a sorting protein limiting beta-amyloid production, in Alzheimer disease cerebrospinal fluid. Archives of Neurology. 66: 448-57. PMID 19364929 DOI: 10.1001/archneurol.2009.22  0.52
2009 Filoteo JV, Salmon DP, Schiehser DM, Kane AE, Hamilton JM, Rilling LM, Lucas JA, Zizak V, Galasko DR. Verbal learning and memory in patients with dementia with Lewy bodies or Parkinson's disease with dementia. Journal of Clinical and Experimental Neuropsychology. 31: 823-34. PMID 19221922 DOI: 10.1080/13803390802572401  0.52
2009 Borenstein AR, Mortimer JA, Schellenberg GD, Galasko D, McGeer PL, Steele JC. The ALS/PDC syndrome of Guam and the cycad hypothesis. Neurology. 72: 473, 476; author rep. PMID 19188582 DOI: 10.1212/01.wnl.0000344257.59693.cf  0.52
2009 Wiltfang J, Lewczuk P, Riederer P, Grünblatt E, Hock C, Scheltens P, Hampel H, Vanderstichele H, Iqbal K, Galasko D, Lannfelt L, Otto M, Esselman H, Henkel AW, Kornhuber J, et al. Consensus paper of the WFSBP task force on biological markers of dementia: The role of CSF and blood analysis in the early and differential diagnosis of dementia | Trabalho de consenso de força-tarefa da WFSBP sobre marcadores biológicos das demências: Contribuição da análise do LCR e do sangue para o diagnóstico precoce e diferencial das demências Revista De Psiquiatria Clinica. 36: 1-16. DOI: 10.1590/S0101-60832009000700001  0.52
2008 Hamilton JM, Salmon DP, Galasko D, Raman R, Emond J, Hansen LA, Masliah E, Thal LJ. Visuospatial deficits predict rate of cognitive decline in autopsy-verified dementia with Lewy bodies. Neuropsychology. 22: 729-37. PMID 18999346 DOI: 10.1037/a0012949  0.52
2008 Vuletic S, Li G, Peskind ER, Kennedy H, Marcovina SM, Leverenz JB, Petrie EC, Lee VM, Galasko D, Schellenberg GD, Albers JJ. Apolipoprotein E highly correlates with AbetaPP- and tau-related markers in human cerebrospinal fluid. Journal of Alzheimer's Disease : Jad. 15: 409-17. PMID 18997294 DOI: 10.3233/JAD-2008-15307  0.52
2008 Bekris LM, Millard SP, Galloway NM, Vuletic S, Albers JJ, Li G, Galasko DR, DeCarli C, Farlow MR, Clark CM, Quinn JF, Kaye JA, Schellenberg GD, Tsuang D, Peskind ER, et al. Multiple SNPs within and surrounding the apolipoprotein E gene influence cerebrospinal fluid apolipoprotein E protein levels. Journal of Alzheimer's Disease : Jad. 13: 255-66. PMID 18430993  0.52
2008 Rascovsky K, Salmon DP, Hansen LA, Galasko D. Distinct cognitive profiles and rates of decline on the Mattis Dementia Rating Scale in autopsy-confirmed frontotemporal dementia and Alzheimer's disease. Journal of the International Neuropsychological Society : Jins. 14: 373-83. PMID 18419836 DOI: 10.1017/S135561770808051X  0.52
2008 Van Deerlin VM, Leverenz JB, Bekris LM, Bird TD, Yuan W, Elman LB, Clay D, Wood EM, Chen-Plotkin AS, Martinez-Lage M, Steinbart E, McCluskey L, Grossman M, Neumann M, Wu IL, ... ... Galasko DR, et al. TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. The Lancet. Neurology. 7: 409-16. PMID 18396105 DOI: 10.1016/S1474-4422(08)70071-1  0.52
2008 Leverenz JB, Hamilton R, Tsuang DW, Schantz A, Vavrek D, Larson EB, Kukull WA, Lopez O, Galasko D, Masliah E, Kaye J, Woltjer R, Clark C, Trojanowski JQ, Montine TJ. Empiric refinement of the pathologic assessment of Lewy-related pathology in the dementia patient. Brain Pathology (Zurich, Switzerland). 18: 220-4. PMID 18241240 DOI: 10.1111/j.1750-3639.2007.00117.x  0.52
2008 Pan S, Rush J, Peskind ER, Galasko D, Chung K, Quinn J, Jankovic J, Leverenz JB, Zabetian C, Pan C, Wang Y, Jung HO, Gao J, Zhang J, Montine T. Application of targeted quantitative proteomics analysis in human cerebrospinal fluid using a liquid chromatography matrix-assisted laser desorption/ionization time-of-flight tandem mass spectrometer (LC MALDI TOF/TOF) platform Journal of Proteome Research. 7: 720-730. PMID 18186601 DOI: 10.1021/pr700630x  0.52
2008 Geser F, Winton MJ, Kwong LK, Xu Y, Xie SX, Igaz LM, Garruto RM, Perl DP, Galasko D, Lee VM, Trojanowski JQ. Pathological TDP-43 in parkinsonism-dementia complex and amyotrophic lateral sclerosis of Guam. Acta Neuropathologica. 115: 133-45. PMID 17713769 DOI: 10.1007/s00401-007-0257-y  0.52
2007 Galasko DR, Graff-Radford N, May S, Hendrix S, Cottrell BA, Sagi SA, Mather G, Laughlin M, Zavitz KH, Swabb E, Golde TE, Murphy MP, Koo EH. Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individuals. Alzheimer Disease and Associated Disorders. 21: 292-9. PMID 18090435 DOI: 10.1097/WAD.0b013e31815d1048  0.52
2007 Rascovsky K, Hodges JR, Kipps CM, Johnson JK, Seeley WW, Mendez MF, Knopman D, Kertesz A, Mesulam M, Salmon DP, Galasko D, Chow TW, Decarli C, Hillis A, Josephs K, et al. Diagnostic criteria for the behavioral variant of frontotemporal dementia (bvFTD): current limitations and future directions. Alzheimer Disease and Associated Disorders. 21: S14-8. PMID 18090417 DOI: 10.1097/WAD.0b013e31815c3445  0.52
2007 Mickes L, Wixted JT, Fennema-Notestine C, Galasko D, Bondi MW, Thal LJ, Salmon DP. Progressive impairment on neuropsychological tasks in a longitudinal study of preclinical Alzheimer's disease. Neuropsychology. 21: 696-705. PMID 17983283 DOI: 10.1037/0894-4105.21.6.696  0.52
2007 Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, Friedman LF, Galasko DR, Jutel M, Karydas A, Kaye JA, Leszek J, Miller BL, Minthon L, Quinn JF, et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nature Medicine. 13: 1359-62. PMID 17934472 DOI: 10.1038/nm1653  0.52
2007 Yang W, Woltjer RL, Sokal I, Pan C, Wang Y, Brodey M, Peskind ER, Leverenz JB, Zhang J, Perl DP, Galasko DR, Montine TJ. Quantitative proteomics identifies surfactant-resistant alpha-synuclein in cerebral cortex of Parkinsonism-dementia complex of Guam but not Alzheimer's disease or progressive supranuclear palsy. The American Journal of Pathology. 171: 993-1002. PMID 17675576 DOI: 10.2353/ajpath.2007.070015  0.52
2007 Peavy GM, Lange KL, Salmon DP, Patterson TL, Goldman S, Gamst AC, Mills PJ, Khandrika S, Galasko D. The effects of prolonged stress and APOE genotype on memory and cortisol in older adults. Biological Psychiatry. 62: 472-8. PMID 17544378 DOI: 10.1016/j.biopsych.2007.03.013  0.52
2007 Galasko D, Salmon D, Gamst A, Olichney J, Thal LJ, Silbert L, Kaye J, Brooks P, Adonay R, Craig UK, Schellenberg G, Borenstein AR. Prevalence of dementia in Chamorros on Guam: relationship to age, gender, education, and APOE. Neurology. 68: 1772-81. PMID 17515539 DOI: 10.1212/01.wnl.0000262028.16738.64  0.52
2007 Borenstein AR, Mortimer JA, Schofield E, Wu Y, Salmon DP, Gamst A, Olichney J, Thal LJ, Silbert L, Kaye J, Craig UL, Schellenberg GD, Galasko DR. Cycad exposure and risk of dementia, MCI, and PDC in the Chamorro population of Guam. Neurology. 68: 1764-71. PMID 17515538 DOI: 10.1212/01.wnl.0000262027.31623.b2  0.52
2007 Rascovsky K, Salmon DP, Hansen LA, Thal LJ, Galasko D. Disparate letter and semantic category fluency deficits in autopsy-confirmed frontotemporal dementia and Alzheimer's disease. Neuropsychology. 21: 20-30. PMID 17201527 DOI: 10.1037/0894-4105.21.1.20  0.52
2007 Sundar PD, Yu CE, Sieh W, Steinbart E, Garruto RM, Oyanagi K, Craig UK, Bird TD, Wijsman EM, Galasko DR, Schellenberg GD. Two sites in the MAPT region confer genetic risk for Guam ALS/PDC and dementia. Human Molecular Genetics. 16: 295-306. PMID 17185385 DOI: 10.1093/hmg/ddl463  0.52
2007 Galasko DR. Dementia with Lewy bodies Continuum Lifelong Learning in Neurology. 13: 69-86. DOI: 10.1212/01.CON.0000267236.07498.38  0.52
2006 Riekse RG, Li G, Petrie EC, Leverenz JB, Vavrek D, Vuletic S, Albers JJ, Montine TJ, Lee VM, Lee M, Seubert P, Galasko D, Schellenberg GD, Hazzard WR, Peskind ER. Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid. Journal of Alzheimer's Disease : Jad. 10: 399-406. PMID 17183151 DOI: 10.3233/JAD-2006-10408  0.52
2006 Galasko D, Bennett DA, Sano M, Marson D, Kaye J, Edland SD. ADCS Prevention Instrument Project: assessment of instrumental activities of daily living for community-dwelling elderly individuals in dementia prevention clinical trials. Alzheimer Disease and Associated Disorders. 20: S152-69. PMID 17135809 DOI: 10.1097/01.wad.0000213873.25053.2b  0.36
2006 Ferris SH, Aisen PS, Cummings J, Galasko D, Salmon DP, Schneider L, Sano M, Whitehouse PJ, Edland S, Thal LJ. ADCS Prevention Instrument Project: overview and initial results. Alzheimer Disease and Associated Disorders. 20: S109-23. PMID 17135805 DOI: 10.1097/01.wad.0000213870.40300.21  0.52
2006 Thal LJ, Kawas C, Galasko D, Salmon DP, Sundsmo MP. Robert Katzman honored. Alzheimer Disease and Associated Disorders. 20: S27-8. PMID 16917190 DOI: 10.1097/00002093-200607001-00001  0.52
2006 Peskind ER, Li G, Shofer J, Quinn JF, Kaye JA, Clark CM, Farlow MR, DeCarli C, Raskind MA, Schellenberg GD, Lee VM, Galasko DR. Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition. Archives of Neurology. 63: 936-9. PMID 16831961 DOI: 10.1001/archneur.63.7.936  0.52
2006 Winton MJ, Joyce S, Zhukareva V, Practico D, Perl DP, Galasko D, Craig U, Trojanowski JQ, Lee VM. Characterization of tau pathologies in gray and white matter of Guam parkinsonism-dementia complex. Acta Neuropathologica. 111: 401-12. PMID 16609851 DOI: 10.1007/s00401-006-0053-0  0.52
2006 Thal LJ, Kantarci K, Reiman EM, Klunk WE, Weiner MW, Zetterberg H, Galasko D, Praticò D, Griffin S, Schenk D, Siemers E. The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Disease and Associated Disorders. 20: 6-15. PMID 16493230 DOI: 10.1097/01.wad.0000191420.61260.a8  0.52
2006 Janvin CC, Larsen JP, Salmon DP, Galasko D, Hugdahl K, Aarsland D. Cognitive profiles of individual patients with Parkinson's disease and dementia: comparison with dementia with lewy bodies and Alzheimer's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 21: 337-42. PMID 16211595 DOI: 10.1002/mds.20726  0.52
2005 Peskind ER, Riekse R, Quinn JF, Kaye J, Clark CM, Farlow MR, Decarli C, Chabal C, Vavrek D, Raskind MA, Galasko D. Safety and acceptability of the research lumbar puncture. Alzheimer Disease and Associated Disorders. 19: 220-5. PMID 16327349 DOI: 10.1097/01.wad.0000194014.43575.fd  0.52
2005 Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal LJ. Vitamin E and donepezil for the treatment of mild cognitive impairment. The New England Journal of Medicine. 352: 2379-88. PMID 15829527 DOI: 10.1056/NEJMoa050151  0.52
2004 Hamilton JM, Salmon DP, Galasko D, Delis DC, Hansen LA, Masliah E, Thomas RG, Thal LJ. A comparison of episodic memory deficits in neuropathologically-confirmed Dementia with Lewy bodies and Alzheimer's disease. Journal of the International Neuropsychological Society : Jins. 10: 689-97. PMID 15327716 DOI: 10.1017/S1355617704105043  0.52
2004 Galasko D, Kershaw PR, Schneider L, Zhu Y, Tariot PN. Galantamine maintains ability to perform activities of daily living in patients with Alzheimer's disease Journal of the American Geriatrics Society. 52: 1070-1076. PMID 15209643 DOI: 10.1111/j.1532-5415.2004.52303.x  0.52
2004 Grundman M, Petersen RC, Ferris SH, Thomas RG, Aisen PS, Bennett DA, Foster NL, Jack CR, Galasko DR, Doody R, Kaye J, Sano M, Mohs R, Gauthier S, Kim HT, et al. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Archives of Neurology. 61: 59-66. PMID 14732621 DOI: 10.1001/archneur.61.1.59  0.52
2003 Caligiuri MP, Peavy G, Salmon DP, Galasko DR, Thal LJ. Neuromotor abnormalities and risk for psychosis in Alzheimer's disease. Neurology. 61: 954-8. PMID 14557567  0.52
2003 Frank RA, Galasko D, Hampel H, Hardy J, de Leon MJ, Mehta PD, Rogers J, Siemers E, Trojanowski JQ. Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. Neurobiology of Aging. 24: 521-36. PMID 12714109 DOI: 10.1016/S0197-4580(03)00002-2  0.52
2003 Granholm E, Morris S, Galasko D, Shults C, Rogers E, Vukov B. Tropicamide effects on pupil size and pupillary light reflexes in Alzheimer's and Parkinson's disease. International Journal of Psychophysiology : Official Journal of the International Organization of Psychophysiology. 47: 95-115. PMID 12568941 DOI: 10.1016/S0167-8760(02)00122-8  0.52
2003 Plato CC, Garruto RM, Galasko D, Craig UK, Plato M, Gamst A, Torres JM, Wiederholt W. Amyotrophic lateral sclerosis and parkinsonism-dementia complex of Guam: changing incidence rates during the past 60 years. American Journal of Epidemiology. 157: 149-57. PMID 12522022 DOI: 10.1093/aje/kwf175  0.52
2002 Lange KL, Bondi MW, Salmon DP, Galasko D, Delis DC, Thomas RG, Thal LJ. Decline in verbal memory during preclinical Alzheimer's disease: examination of the effect of APOE genotype. Journal of the International Neuropsychological Society : Jins. 8: 943-55. PMID 12405546 DOI: 10.1017/S1355617702870096  0.52
2002 Ho GJ, Hansen LA, Alford MF, Foster K, Salmon DP, Galasko D, Thal LJ, Masliah E. Age at onset is associated with disease severity in Lewy body variant and Alzheimer's disease. Neuroreport. 13: 1825-8. PMID 12395133  0.52
2002 Weiner MF, Tractenberg RE, Sano M, Logsdon R, Teri L, Galasko D, Gamst A, Thomas R, Thal LJ. No long-term effect of behavioral treatment on psychotropic drug use for agitation in Alzheimer's disease patients. Journal of Geriatric Psychiatry and Neurology. 15: 95-8. PMID 12083600  0.52
2002 Haan MN, Jagust WJ, Galasko D, Kaye J. Effect of extrapyramidal signs and Lewy bodies on survival in patients with Alzheimer disease. Archives of Neurology. 59: 588-93. PMID 11939893  0.52
2002 Galasko D, Salmon DP, Craig UK, Thal LJ, Schellenberg G, Wiederholt W. Clinical features and changing patterns of neurodegenerative disorders on Guam, 1997-2000. Neurology. 58: 90-7. PMID 11781411  0.36
2001 Caligiuri MP, Peavy G, Galasko DR. Extrapyramidal signs and cognitive abilities in Alzheimer's disease. International Journal of Geriatric Psychiatry. 16: 907-11. PMID 11571772 DOI: 10.1002/gps.443  0.52
2000 Galasko D, Salmon D, Craig UK, Wiederholt W. The clinical spectrum of Guam ALS and Parkinson-dementia complex: 1997-1999. Annals of the New York Academy of Sciences. 920: 120-5. PMID 11193140 DOI: 10.1111/j.1749-6632.2000.tb06913.x  0.36
2000 Galasko DR, Gould RL, Abramson IS, Salmon DP. Measuring cognitive change in a cohort of patients with Alzheimer's disease. Statistics in Medicine. 19: 1421-32. PMID 10844707 DOI: 10.1002/(SICI)1097-0258(20000615/30)19:11/12<1421::AID-SIM434>3.0.CO;2-P  0.52
2000 Kuo YM, Kokjohn TA, Kalback W, Luehrs D, Galasko DR, Chevallier N, Koo EH, Emmerling MR, Roher AE. Amyloid-beta peptides interact with plasma proteins and erythrocytes: implications for their quantitation in plasma. Biochemical and Biophysical Research Communications. 268: 750-6. PMID 10679277 DOI: 10.1006/bbrc.2000.2222  0.52
2000 Bennett DA, Galasko DR, Knopman DS, Kuhn D. Disease-a-month: Introduction Disease-a-Month. 46: 729-780.  0.52
2000 Sabbagh MN, Galasko D, Koo E, Thal LJ. Amyloid-β and treatment opportunities for Alzheimer's disease Journal of Alzheimer's Disease. 2: 231-259.  0.52
1998 Ellis RJ, Seubert P, Motter R, Galasko D, Deutsch R, Heaton RK, Heyes MP, McCutchan JA, Atkinson JH, Grant I. Cerebrospinal fluid tau protein is not elevated in HIV-associated neurologic disease in humans. HIV Neurobehavioral Research Center Group (HNRC). Neuroscience Letters. 254: 1-4. PMID 9780077 DOI: 10.1016/S0304-3940(98)00549-7  0.52
1998 Galasko D, Chang L, Motter R, Clark CM, Kaye J, Knopman D, Thomas R, Kholodenko D, Schenk D, Lieberburg I, Miller B, Green R, Basherad R, Kertiles L, Boss MA, et al. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Archives of Neurology. 55: 937-45. PMID 9678311 DOI: 10.1001/archneur.55.7.937  0.52
1997 Galasko D, Clark C, Chang L, Miller B, Green RC, Motter R, Seubert P. Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease. Neurology. 48: 632-5. PMID 9065538 DOI: 10.1212/WNL.48.3.632  0.52
1996 Salmon DP, Galasko D, Hansen LA, Masliah E, Butters N, Thal LJ, Katzman R. Neuropsychological deficits associated with diffuse Lewy body disease. Brain and Cognition. 31: 148-65. PMID 8811990 DOI: 10.1006/brcg.1996.0039  0.52
1996 Ellis RJ, Caligiuri M, Galasko D, Thal LJ. Extrapyramidal motor signs in clinically diagnosed Alzheimer disease. Alzheimer Disease and Associated Disorders. 10: 103-14. PMID 8727172 DOI: 10.1097/00002093-199601020-00008  0.52
1996 Katzman R, Galasko DR, Saitoh T, Chen X, Pay MM, Booth A, Thomas RG. Apolipoprotein-epsilon4 and head trauma: Synergistic or additive risks? Neurology. 46: 889-91. PMID 8618734  0.52
1995 Galasko D, Edland SD, Morris JC, Clark C, Mohs R, Koss E. The consortium to establish a registry for alzheimer's disease (cerad).: Part xi. clinical milestones in patients with alzheimer's disease followed over 3 years Neurology. 45: 1451-1455. PMID 7644039 DOI: 10.1212/WNL.45.8.1451  0.52
1995 Motter R, Vigo-Pelfrey C, Kholodenko D, Barbour R, Johnson-Wood K, Galasko D, Chang L, Miller B, Clark C, Green R. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Annals of Neurology. 38: 643-8. PMID 7574461 DOI: 10.1002/ana.410380413  0.52
1994 Galasko D, Hansen LA, Katzman R, Wiederholt W, Masliah E, Terry R, Hill LR, Lessin P, Thal LJ. Clinical-neuropathological correlations in Alzheimer's disease and related dementias. Archives of Neurology. 51: 888-95. PMID 8080388 DOI: 10.1001/archneur.1994.00540210060013  0.52
1994 Galasko D, Saitoh T, Xia Y, Thal LJ, Katzman R, Hill LR, Hansen L. The apolipoprotein E allele epsilon 4 is overrepresented in patients with the Lewy body variant of Alzheimer's disease. Neurology. 44: 1950-1. PMID 7936253 DOI: 10.1212/WNL.44.10.1950  0.52
1994 Hansen LA, Galasko D, Samuel W, Xia Y, Chen X, Saitoh T. Apolipoprotein-E epsilon-4 is associated with increased neurofibrillary pathology in the Lewy body variant of Alzheimer's disease. Neuroscience Letters. 182: 63-5. PMID 7891889 DOI: 10.1016/0304-3940(94)90206-2  0.4
1993 Galasko D, Abramson I, Corey-Bloom J, Thal LJ. Repeated exposure to the Mini-Mental State Examination and the Information-Memory-Concentration Test results in a practice effect in Alzheimer's disease. Neurology. 43: 1559-63. PMID 8351011  0.52
1992 Caligiuri MP, Galasko DR. Quantifying drug-induced changes in parkinsonian rigidity using an instrumental measure of activated stiffness. Clinical Neuropharmacology. 15: 1-12. PMID 1576594  0.52
1991 Galasko D, Corey-Bloom J, Thal LJ. Monitoring progression in Alzheimer's disease. Journal of the American Geriatrics Society. 39: 932-41. PMID 1842209  0.52
1990 Galasko D, Kwo-on-Yuen PF, Klauber MR, Thal LJ. Neurological findings in Alzheimer's disease and normal aging. Archives of Neurology. 47: 625-7. PMID 2346387  0.52
1990 Galasko D, Klauber MR, Hofstetter CR, Salmon DP, Lasker B, Thal LJ. The Mini-Mental State Examination in the early diagnosis of Alzheimer's disease. Archives of Neurology. 47: 49-52. PMID 2294894 DOI: 10.1001/archneur.1990.00530010061020  0.52
Show low-probability matches.